Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Abstract
Background: Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery. Little is known how malaria affects glucose-6-phosphate dehydrogenase (G6PD) activity and whether changes in activity when patients present may lead qualitative tests, like the fluorescent spot test (FST), to misdiagnose G6PD deficient (G6PDd) patients as G6PD normal (G6PDn). Giving primaquine or tafenoquine to such patients could result in severe haemolysis. Methods: We investigated the G6PD genotype, G6PD enzyme activity over time and the baseline FST phenotype in Cambodians with acute P . vivax malaria treated with 3-day dihydroartemisinin piperaquine and weekly primaquine, 0·75 mg/kg x8 doses. Results: Of 75 recruited patients (males 63), aged 5–63 years (median 24), 15 were G6PDd males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PDn; 6 patients had α/β-thalassaemia and 26 had HbE. Median (range) Day0 G6PD activities were 0·85 U/g Hb (0·10–1·36) and 11·4 U/g Hb (6·67–16·78) in G6PDd and G6PDn patients, respectively, rising significantly to 1·45 (0·36–5·54, p<0.01) and 12·0 (8·1–17·4, p = 0.04) U/g Hb on Day7, then falling to ~Day0 values by Day56. Day0 G6PD activity did not correlate (p = 0.28) with the Day0 reticulocyte counts but both correlated over time. The FST diagnosed correctly 17/18 G6PDd patients, misclassifying one heterozygous female as G6PDn. Conclusions: In Cambodia, acute P . vivax malaria did not elevate G6PD activities in our small sample of G6PDd patients to levels that would result in a false normal qualitative test. Low G6PDd enzyme activity at disease presentation increases upon parasite clearance, parallel to reticulocytosis. More work is needed in G6PDd heterozygous females to ascertain the effect of P . vivax on their G6PD activities. Trial registration: The trial was registered (ACTRN12613000003774) with the Australia New Zealand Clinical trials ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363399&isReview=true ).
Overview
CoChat Summary
TL;DR
In Cambodian patients with acute *P. vivax* malaria treated with dihydroartemisinin-piperaquine and weekly primaquine, G6PD activity rose modestly by Day 7 in both G6PD-deficient and G6PD-normal patients and returned toward baseline by Day 56, without elevating G6PD-deficient patients into the normal range. The fluorescent spot test correctly identified 17/18 G6PD-deficient patients, misclassifying one heterozygous female as normal.
Key findings
- Among 75 recruited patients (63 males; median age 24, range 5–63), 15 were G6PD-deficient males (14 Viangchan, 1 Canton), 3 were G6PD Viangchan heterozygous females, and 57 were G6PD normal; 6 had α/β-thalassaemia and 26 had HbE.
- Median Day 0 G6PD activity was 0.85 U/g Hb (0.10–1.36) in G6PD-deficient patients and 11.4 U/g Hb (6.67–16.78) in G6PD-normal patients, rising significantly by Day 7 to 1.45 U/g Hb (0.36–5.54, p<0.01) and 12.0 U/g Hb (8.1–17.4, p=0.04), respectively, then falling to ~Day 0 values by Day 56.
- Day 0 G6PD activity did not correlate with Day 0 reticulocyte counts (p=0.28), but over time G6PD activity was explained only by changes in reticulocyte counts in mixed-effects modelling (coefficient 0.29, 95% CI 0.039–0.52, p=0.024).
- The fluorescent spot test correctly diagnosed 17/18 G6PD-deficient patients (sensitivity 94.4%, 95% CI 72.7–99.8) and 55/57 G6PD-normal patients (specificity 96.5%, 95% CI 87.9–99.6), misclassifying one heterozygous female as G6PD normal.
Methods
- From January 2013 to January 2014, 75 non-pregnant Cambodians aged >1 year with uncomplicated *P. vivax* received dihydroartemisinin-piperaquine on Days 0–2 and eight weekly primaquine doses (0.75 mg/kg, Days 0–49); 67 completed follow-up to Day 56.
- Assessments included G6PD genotype by PCR, G6PD enzyme activity, baseline fluorescent spot test, reticulocyte counts, haemoglobin, Hb electrophoresis, full blood count and routine biochemistry at Days 0, 7, 28, and 56; G6PD activity in thalassaemic patients was adjusted for low mean corpuscular volume.
- Analysis used Stata v14 with chi-squared/Fisher tests, paired/unpaired t or non-parametric tests, FST sensitivity/specificity against genotype, backward stepwise multivariate regression, linear mixed-effects modelling, and Pearson correlation.
Limitations
- The authors state the study was limited by the small number of G6PD-deficient patients, very few G6PD-deficient heterozygous females, and almost all having one variant (G6PD Viangchan); more data are needed across variants and in heterozygous females, and in falciparum-infected patients.
- The authors state there was no no-primaquine arm, which would have helped separate effects of malaria itself and its treatment on G6PD activity and reticulocyte counts over time.
- Evident from the text: four inappropriately low G6PD-normal values were excluded (probably due to delayed analysis) and 39 values were missing due to loss to follow-up or not being done; one heterozygous female’s Day 0 value may have been spuriously low for technical reasons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 18 Not checked · 39 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, there was a significant correlation [r = 0.64 (p = 0.001)] with the baseline temperatures only in the G6PDd patients (S4 Fig).”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Reticulocyte counts
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there was no significant effect of thalassaemia/Hb E (S3 Fig).”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The FST diagnosed correctly 17/18 G6PDd patients, misclassifying one heterozygous female as G6PDn.”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Abstract > Results
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that baseline G6PD activity was independent of the reticulocyte count, as reported previously [27], but, over 56 days, changes in G6PD activity correlated with changes in the reticulocyte counts.”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By D56, the mean G6PD activities were not significantly different vs. D0 (p = 0·44).”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
15 more claims
Create a free account to see all 57 claims and to verify the 34 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 10
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Panel A: G6PD normal patients: the Pearson correlation coefficient, r, was 0.14, adjusted R2 0.34 (p<0.001).”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
Reported 0.34 · recomputed 0.0196
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
“G6PD activity increased in 42 (13 G6PDd) patients, fell in 19 (2 G6PDn) and remained unchanged in one”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Patient baseline characteristics
“The 18 G6PDd patients comprised 15 hemizygous males (14 G6PD Viangchan and 1 G6PD Canton) and 3 G6PD heterozygous Viangchan females.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
“but not in the G6PDd arm (p = 0.81).”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Results > Time course of G6PD activity
“Panel B: G6PD deficient patients: r = 0.063, aR2 = -0.063 (p = 0.64).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Materials and methods > Trial design, study site and conduct
“(i) 10–17 kg, 7.5 mg”
§ Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria > Materials and methods > Trial design, study site and conduct
“(ii) 10–25 kg, 15 mg”
Citations
Cites
Glucose-6-phosphate dehydrogenase deficiency
Luzzatto, L., Ally, M., & Notaro, R. (2020) · Blood · doi:10.1182/blood.2019000944 · Cited by 406
Self-citationTARLOV, A. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620140081013 · Cited by 273
Glucose-6-Phosphate Dehydrogenase Deficiency and Antimalarial Drug Development
Beutler, E., Duparc, S., & _, _. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.779 · Cited by 215
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N. H., Cheah, P. Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31285-1 · Cited by 178
Self-citationShanks, G. D., Oloo, A. J., Aleman, G. M., Ohrt, C., Klotz, F. W., Braitman, D., Horton, J., & Brueckner, R. (2001) · Clinical Infectious Diseases · doi:10.1086/324081 · Cited by 168
Chu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C., Chowwiwat, N., Raksapraidee, R., Wilairisak, P., Phyo, A. P., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002224 · Cited by 146
Kim, S., Nguon, C., Guillard, B., Duong, S., Chy, S., Sum, S., Nhem, S., Bouchier, C., Tichit, M., Christophel, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028357 · Cited by 124
Self-citationFirst-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial
Brueckner, R. P., Lasseter, K. C., Lin, E. T., & Schuster, B. G. (1998) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1998.58.645 · Cited by 113
Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission
White, M. T., Karl, S., Battle, K. E., Hay, S. I., Mueller, I., & Ghani, A. C. (2014) · eLife · doi:10.7554/elife.04692 · Cited by 111
Pamba, A., Richardson, N. D., Carter, N., Duparc, S., Premji, Z., Tiono, A. B., & Luzzatto, L. (2012) · Blood · doi:10.1182/blood-2012-03-416032 · Cited by 104
Self-citationPrimaquine-induced haemolysis in females heterozygous for G6PD deficiency
Chu, C. S., Bancone, G., Nosten, F., White, N. J., & Luzzatto, L. (2018) · Malaria Journal · doi:10.1186/s12936-018-2248-y · Cited by 100
Self-citationRueangweerayut, R., Bancone, G., Harrell, E. J., Beelen, A. P., Kongpatanakul, S., Möhrle, J. J., Rousell, V., Mohamed, K., Qureshi, A., Narayan, S., et al. (2017) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0779 · Cited by 100
Self-citationMarks, P. A., & Johnson, A. B. (1958) · Journal of Clinical Investigation · doi:10.1172/jci103746 · Cited by 99
Kheng, S., Muth, S., Taylor, W. R. J., Tops, N., Kosal, K., Sothea, K., Souy, P., Kim, S., Char, C. M., Vanna, C., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0441-1 · Cited by 84
Self-citationFavism: clinical and biochemical data.
Kattamis, C., Kyriazakou, M., & Chaidas, S. (1969) · Journal of Medical Genetics · doi:10.1136/jmg.6.1.34 · Cited by 78
Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency
Morelli, A., Benatti, U., Gaetani, G. F., & De Flora, A. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.4.1979 · Cited by 68
Roca-Feltrer, A., Khim, N., Kim, S., Chy, S., Canier, L., Kerleguer, A., Tor, P., Chuor, C. M., Kheng, S., Siv, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116143 · Cited by 58
Self-citationBancone, G., Menard, D., Khim, N., Kim, S., Canier, L., Nguong, C., Phommasone, K., Mayxay, M., Dittrich, S., Vongsouvath, M., et al. (2019) · Malaria Journal · doi:10.1186/s12936-019-2652-y · Cited by 50
Self-citationBrito-Sousa, J. D., Santos, T. C., Avalos, S., Fontecha, G., Melo, G. C., Val, F., Siqueira, A. M., Alecrim, G. C., Bassat, Q., Lacerda, M. V. G., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz122 · Cited by 50
G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients
Khim, N., Benedet, C., Kim, S., Kheng, S., Siv, S., Leang, R., Lek, S., Muth, S., Chea, N., Chuor, C. M., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-171 · Cited by 47
Self-citationSatyagraha, A. W., Sadhewa, A., Elvira, R., Elyazar, I., Feriandika, D., Antonjaya, U., Oyong, D., Subekti, D., Rozi, I. E., Domingo, G. J., et al. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004457 · Cited by 41
Self-citationThe Course of Experimentally Induced Hemolytic Anemia in a Primaquine-Sensitive Caucasian
PANNACCIULLI, I., TIZIANELLO, A., AJMAR, F., & SALVIDIO, E. (1965) · Blood · doi:10.1182/blood.v25.1.92.92 · Cited by 39
Espino, F. E., Bibit, J.-A., Sornillo, J. B., Tan, A., von Seidlein, L., & Ley, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148172 · Cited by 36
Piomelli, S., & Siniscalco, M. (1969) · British Journal of Haematology · doi:10.1111/j.1365-2141.1969.tb00435.x · Cited by 34
Baird, J. K., Dewi, M., Subekti, D., Elyazar, I., & Satyagraha, A. W. (2015) · Translational Research · doi:10.1016/j.trsl.2014.09.009 · Cited by 31
Self-citationDetection of Occult Glomerular Dysfunction in Glucose Six Phosphate Dehydrogenase Deficiency Anemia
Hakeem, G. L. A., Naem, E. A., Swelam, S. H., Aboul-Fotoh, L. E.-M., Mazary, A. A. A., Fadeil, A. A., & Hafez, A. H. A. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.038 · Cited by 19
Reticulocyte quantification by Coulter MAXM VCS (volume, conductivity, light scatter) technology
Buttarello, M., Bulian, P., Prà, M. D., Barbera, P., & Rizzotti, P. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.12.1930 · Cited by 16
Primaquine for all: is it time to simplify malaria treatment in co-endemic areas?
Lacerda, M., & Bassat, Q. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30612-1 · Cited by 13
The Mechanism of Haemolysis in Favism
Panizon, F., & Zacchello, F. (2009) · Acta Haematologica · doi:10.1159/000209522 · Cited by 9
Jaundice Associated with Lobar Pneumonia
TUGWELL, P., & WILLIAMS, A. O. (1977) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067497 · Cited by 2
Some clinical and biochemical aspects of favism in childhood.
Ca, K. (1969) · PubMed · Cited by 2
(1954) · PubMed
(1960) · Europe PMC (PubMed Central)
(1954) · PubMed
(1971) · PubMed
Research works printed but not linked: 1
- JD Brito-Sousa, 2019, Clinical Spectrum of Primaquine-induced Hemolysis in G6PD Deficiency: A Nine-Year Hospitalization-Based Study from the Brazilian Amazon, Clinical infectious diseases: an official publication of the Infectious Diseases Society of America
Cited by
Sadhewa, A., Cassidy-Seyoum, S. A., Acharya, S., Devine, A., Price, R. N., Mwaura, M., Thriemer, K., & Ley, B. (2023) · Pathogens · doi:10.3390/pathogens12050650 · Cited by 39
Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria
Ley, B., Alam, M. S., Satyagraha, A. W., Phru, C. S., Thriemer, K., Tadesse, D., Shibiru, T., Hailu, A., Kibria, M. G., Hossain, M. S., et al. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010406 · Cited by 19
Case Series of Primaquine-Induced Haemolytic Events in Controlled Trials with G6PD Screening
Kosasih, A. A., James, R., Châu, N. H., Karman, M. M., Panggalo, L. V., Wini, L., Thanh, N. V., Obadia, T., Satyagraha, A. W., Asih, P. B. S., et al. (2023) · Pathogens · doi:10.3390/pathogens12091176 · Cited by 10
Self-citationComparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice
Fasinu, P. S., Chaurasiya, N. D., Nanayakkara, N. P. D., Wang, Y., Herath, H. M. T. B., Avula, B., McChesney, J. D., Jollow, D. J., Walker, L., & Tekwani, B. L. (2022) · Malaria Journal · doi:10.1186/s12936-022-04054-4 · Cited by 6
Dahuron, L., Goungounga, J. A., Dramé, M., Douine, M., Nacher, M., Blaise, T., Mosnier, É., Musset, L., Fouillet, M., Djossou, F., et al. (2024) · Malaria Journal · doi:10.1186/s12936-024-04973-4 · Cited by 1
Metadata
- Authors
- Taylor, W. R. J., Kim, S., Kheng, S., Muth, S., Tor, P., Christophel, E., Mukaka, M., Kerleguer, A., Luzzatto, L., Baird, J. K., & Menard, D.
- Affiliations
- Cambodia National Malaria Center (KH)
- Institut Pasteur du Cambodge (KH)
- World Health Organization Regional Office for the Western Pacific (PH)
- University of Oxford (GB)
- Muhimbili University of Health and Allied Sciences (TZ)
- Eijkman Institute for Molecular Biology (ID)
- Corresponding author
- Taylor, Walter R. J.
- Venue
- PLOS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-09-08
- Volume
- 15
- Issue
- 9
- Pages
- e0009690
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- PMC
- PMC8452019
- OpenAlex
- W3197377802
- Semantic Scholar
- daba9d27a4840ef19e0a2c40c2d6fdf247452ba9
- Cited by
- 9
- References
- 35
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 3
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-09-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS neglected tropical diseases (publishedVersion, cc-by)
- Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- World Health Organization
- France Expertise International
- Wellcome Trust (B9RJIXO)
- French Ministry of Foreign Affairs
- APMEN fellowship grant (103-09)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- glucose-6-phosphate dehydrogenase, glucose-6-phosphate dehydrogenase deficiency, vivax malaria, primaquine, tafenoquine, hemolysis, reticulocytosis, reticulocyte count, fluorescent spot test, dihydroartemisinin-piperaquine, thalassemia, HbE, Cambodia
- MeSH terms
- Adolescent, Adult, Aged, Antimalarials, Cambodia, Child, Child, Preschool, Erythrocytes, Female, Genotype, Glucosephosphate Dehydrogenase, Hemoglobins, Hemolysis, Humans, Male, Middle Aged, Primaquine, Malaria, Vivax, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.